Investor Relations

Press Releases

Date Title and Summary Additional Formats
Toggle Summary ELAD Phase IIB Data Presented at ATC
Data from Phase 2b Study of ELAD® Presented at the 2012 American Transplant Congress
View HTML
Toggle Summary ELAD Phase IIB Data Presented at ILTS
Data from Phase 2b Study of ELAD® Presented at International Liver Transplant Society Meeting.
View HTML
Toggle Summary Top Ranked Equity Analyst Joins Vital Therapies, Inc.
Top Ranked Equity Analyst Joins Vital Therapies, Inc. SAN DIEGO , March 19, 2012 /PRNewswire/ -- Vital Therapies, Inc., a development stage biotechnology company focused on allogeneic cellular therapy for acute liver failure, today announced that it has appointed Duane Nash , MD, JD, MBA, as
View HTML
Toggle Summary Three-year follow-up data confirm safety and survival benefit in Chinese liver failure patients treated with ELAD®
Three-year follow-up data confirm safety and survival benefit in Chinese liver failure patients treated with ELAD ®
View HTML
Toggle Summary Vital Therapies Expands SILVER Trial to Saudi Arabia
Vital Therapies Expands SILVER Trial to Saudi Arabia
View HTML
Toggle Summary Bioartificial Human Liver Therapy Trial Progressing
Bioartificial Human Liver Therapy Trial Progressing SAN DIEGO , June 8 /PRNewswire/ -- Vital Therapies, Inc., (VTI) is pleased to announce that the first two subjects have been enrolled at King's College Hospital in London in the expansion of its SILVER ( S tabilization I n L i VER failure)
View HTML
Toggle Summary Vital Therapies Initiates Liver Stabilization Trial
Pivotal ELAD Study in United States and Europe
View HTML
Toggle Summary Vital new hope for Liver failure
Vital new hope for Liver failure
View HTML
Toggle Summary Vital Therapies Plans Phase III Trials for September
Vital Therapies Plans Phase III Trials for September
View HTML
Toggle Summary Liver device helps man survive until transplant
Liver device helps man survive until transplant
View HTML